PLI Pharma

Imagine a country famous for its finished, beautifully packaged bread, that had quietly stopped growing its own wheat decades ago, buying almost all of it from one overseas supplier because that supplier had simply become cheaper. India's pharmaceutical industry, celebrated globally as the pharmacy of the world for finished generic medicines, faced almost exactly this problem with Active Pharmaceutical Ingredients, the actual chemical wheat behind every tablet.

Over decades, cheaper Chinese API production progressively drove many Indian manufacturers out of bulk drug and intermediate manufacturing, even as India kept excelling at the downstream formulation step, turning API into finished tablets and capsules. This left India's celebrated generics industry with an uncomfortable dependency: excellent at finishing the product, heavily reliant on a foreign supplier, chiefly China, for a meaningful share of the core chemical inputs.

The PLI Pharma scheme, running from 2020-21 through 2028-29 with an original outlay of Rs 15,000 crore, was designed to reverse this specific problem, financially incentivising Indian companies to rebuild domestic capacity for critical APIs, key starting materials and drug intermediates that had become almost entirely import-dependent, rather than subsidising the already-strong formulation business.

The push accelerated sharply more recently: in December 2025, the government announced a further Rs 60,000 crore API-focused package specifically aimed at cutting import dependence, alongside earlier initiatives like dedicated Bulk Drug Parks, 27 greenfield parks and 13 medical device plants inaugurated in a single push in March 2024, providing common infrastructure for API manufacturers the same way Solar Parks and Defence Corridors do for their own industries.

Whenever India's pharmaceutical self-reliance is discussed, PLI Pharma and the newer API push are the specific policy tools aimed not at the industry's already-celebrated strength, finished generics, but at quietly rebuilding the upstream chemical capability that strength had come to depend on someone else for.